Roche COVID-19 Response | Questions About Our Medicines? Visit medinfo.roche.com
Retrospective analysis: erlotinib vs gefitinib in Asian patients with newly diagnosed brain metastases
Patients with exon 19 EGFR mutations and newly diagnosed brain metastases experienced significantly longer overall survival and PFS when treated with erlotinib, compared with patients treated with gefitinib.1
Study overview1
- This retrospective analysis examined clinical outcomes of Asian patients with EGFR Mut+ NSCLC and newly diagnosed brain metastases, who were treated with either erlotinib or gefitinib.
Key Results
Overall survival1
Patients receiving erlotinib had a statistically significant longer median overall survival than patients treated with gefitinib (p=0.033).
Progression-free survival1
Patients receiving erlotinib had a statistically significant longer median PFS than patients treated with gefitinib (p=0.014).
Data of preparation February 2020- M-XX-00000785 - © 2020
This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) the United Kingdom (UK), and Australia (AU) who are interested in information on TARCEVA®. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details.